QIAGEN and WuXi AppTec Enter into Partnership Agreement for Molecular Biomarker Development
Shanghai - January 11, 2010 - QIAGEN Asia Pacific and WuXi AppTec (BVI) Inc. today announced a partnership to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases, with QIAGEN providing a complete portfolio of instrumentation, training, and consumables and WuXi AppTec providing laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately.
Under the terms of the partnership agreement, WuXi AppTec will also work with QIAGEN to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN intends to bring to market. WuXi AppTec will use QIAGEN's technologies for a broad range of applications in support of drug discovery and development on behalf of the company's and QIAGEN's customers. Both companies are working closely to identify additional opportunities to expand their relationship.
"We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery, development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry."
"WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers."
QIAGEN and Drug Discovery:
QIAGEN's sample and assay technologies are an integral part of research and development laboratories at many of the world's leading pharmaceutical companies. The company offers innovative technologies for each stage of drug development, from the fundamental pharmaceutical research stage via preclinical and clinical studies to the commercialization of new products. By supplying disease- and pathway-focused panels, QIAGEN contributes to the discovery and validation engines of biomedical and pharmaceutical institutions and can catalyze the development of novel molecular diagnostic assays.
The announcement of the partnership with WuXi AppTec follows QIAGEN's recent acquisitions of DxS Ltd. and SABiosciences Corporation in the biomarker and personalized medicine field. These acquisitions bring additional technologies and expertise to the QIAGEN portfolio, allowing biomedical researchers and pharmaceutical companies to facilitate and accelerate the discovery and validation of biomarkers. QIAGEN also recently opened its new Asia headquarters in Shanghai's Zhangjiang High-Technology Park, a major pharmaceutical R&D hub in China, facilitating industry-leading support for its many pharmaceutical customers.
About QIAGEN Asia:
QIAGEN Asia is the company's fastest-growing division. QIAGEN began its strategic expansion into Asia in 2005 and currently maintains 10 Asian offices with over 450 employees in China, Korea, Malaysia, Singapore, and India. Including the subsidiary in Japan, these Asian operations currently contribute approximately 13 percent to QIAGEN's overall net sales. In 2006, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the company's strategic initiatives in the Asia Pacific molecular testing market.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
About WuXi AppTec:
WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout the pharmaceutical and medical-device R&D process. WuXi AppTec's services are designed to help its global partners to improve the success, shorten the time, and reduce the cost of research and development.
SAFE HARBOR STATEMENT
Statements regarding QIAGEN contained in this release that are not historical facts are forward-looking statements, including statements about the potential outcomes and benefits of the partnership with WuXi AppTec, our products, markets, strategy, and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics); variability of our operating results; commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics); our relationships with customers, suppliers and strategic partners; competition; changes in technology; fluctuations in demand; regulatory requirements; identifying, developing and producing integrated products differentiated from our competitors' products; market acceptance of our products; and integration of acquired technologies and businesses. For further information, refer to QIAGEN's filings with the SEC, including our Annual Report on Form 20-F for the year ended December 31, 2008. Information in this release is as of the date of the release, and the company undertakes no duty to update this information unless required by law.